Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 12/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17026489 | 0.84 | TYMP (0.54) | TYMP | |
| SCHEMBL17026488 | 0.84 | TYMP (0.54) | TYMP | |
| SCHEMBL16964907 | 0.84 | TYMP (0.55) | TYMP | |
| SCHEMBL16964904 | 0.84 | TYMP (0.55) | TYMP | |
| SCHEMBL17026392 | 0.83 | TYMP (0.42) | TYMP | |
| SCHEMBL17026520 | 0.68 | TYMP (0.30) | TYMP | |
| SCHEMBL30274727 | 0.68 | TYMP (0.60) | TYMP | |
| SCHEMBL30274714 | 0.68 | TYMP (0.60) | TYMP | |
| SCHEMBL17026454 | 0.68 | TYMP (0.30) | TYMP | |
| SCHEMBL17037313 | 0.68 | HIF1A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900681-B1 | PHARMACEUTICAL COMPOSITION COMPRISING LIPOPHILIC NUCLEOSIDES | IONOVATION GMBH (DE) | 2019-07-10 | — | — | EP | disclosed |
| US-20190175633-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | IONOVATION GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
| US-20150240295-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | IONOVATION GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240295-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | NCL, NOP2, POLRMT | TYMP 30/4885 |
| US-20190175633-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | NCL, NOP2, HNRNPD | TYMP 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.